as of 11-17-2026 3:45pm EST
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 192.9M | IPO Year: | 2021 |
| Target Price: | $4.00 | AVG Volume (30 days): | 7.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | 16.67 |
| 52 Week Low/High: | $0.30 - $1.63 | Next Earning Date: | 11-12-2026 |
| Revenue: | $4,346,000 | Revenue Growth: | 79.00% |
| Revenue Growth (this year): | 34.4% | Revenue Growth (next year): | 191.30% |
| P/E Ratio: | -0.67 | Index: | |
| Free Cash Flow: | -46682000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
SEC 8-K filings with transcript text
Nov 12, 2026 · 100% conf.
1D
-1.41%
$0.40
Act: +10.73%
5D
-7.29%
$0.38
20D
-16.36%
$0.34
2 ex99-1.htm
Exhibit 99.1
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
EsoGuard® now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume to start the fourth quarter
Conference call and webcast to be held today, November 12, at 8:30 AM EST
NEW YORK, November 12, 2026 - Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM) (“PAVmed”), today provided a business update and reported financial results for the third quarter ended September 30, 2026.
Conference Call and Webcast
The webcast will take place on Thursday, November 12, 2026, at 8:30 AM EST and will be accessible in the investor relations section of the Company’s website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “Lucid Diagnostics Business Update” to join.
Following the conclusion of the conference call, a replay will be available for 30 days in the investor relations section of the Company’s website at luciddx.com.
Business Highlights
“Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test,” said Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer. “This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”
“Our pursuit of EsoGuard’s enormous clinical and commercial opportunity is now substantially less constrained by external factors,” Dr. Aklog added. “Lucid’s near-term growth now depends almost entirely on our team’s commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint.”
Highlights from the third quarter and recent weeks:
●Received first Medicare payments for the EsoGuard® Esophageal DNA Test in October. Lucid began submitting claims in late September after meeting with medical directors at Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction over Lucid’s Texas laboratory, and providing a clinical evidence dossier incorporating their feedback. Lucid has consistently received payments on these claims at EsoGuard’s established Clinical Laboratory Fee Schedule rate of $1,938.01 per test. This Medicare coverage through claim-by-claim adjudication is independent of the pending MolDX Local Coverage Determination (LCD) reconsideration for EsoGuard.
●Immediately and aggressively repositioned commercial efforts to expand EsoGuard testing among at-risk Medicare beneficiaries, representing approximately half of the patients recommended for esophageal precancer testing by professional society guidelines.
●Performed 2,871 EsoGuard tests and recognized revenue of $1.2 million in 3Q26. October was a record month for EsoGuard test volume, with more than 1,800 tests. More than 50,000 EsoGuard tests have been performed since launch.
●Held a formal meeting with CMS leadership on the pending MolDX LCD reconsideration for EsoGuard. The discussion reinforced Lucid’s confidence that the delay is attributable to an administrative backlog. Lucid expects the draft LCD to be published as that backlog begins to clear.
●Continued to expand commercial coverage through the Concert EsoGuard coverage policy, with a total of five Concert client health plans, including the three previously reported, expected to have formally adopted it by year-end.
●Launched Lucid’s first two U.S. Department of Veterans Affairs (VA) programs, with a robust pipeline of additional VA centers behind them. Lucid continues to expect the VA to be a meaningful long-term contributor to its commercial activity and revenue.
●Announced billing and coding milestones, including a new Category III CPT code for EsoCheck cell collection and a proposed ICD-10 diagnosis code for positive EsoGuard results, which will make EsoGuard and EsoCheck easier to bill, track and integrate into clinical practice.
●Announced publication of an 11,991-patient real-world EsoGuard study, the largest peer-reviewed study of nonendoscopic esophageal precancer testing to date. Sampling with the EsoCheck® Esophageal Cell Collection Device was successful in 95% of patients and averaged less than two minutes. The procedure was well tolerated, with no reported de
Aug 13, 2026 · 100% conf.
1D
+3.50%
$1.00
Act: +0.29%
5D
+12.74%
$1.09
Act: -0.47%
20D
+8.05%
$1.04
false 0001799011
0001799011
2026-08-13 2026-08-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): August 13, 2026
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
360 Madison Avenue, 25thFloor, New York, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (917) 813-1828
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 13, 2026, Lucid Diagnostics Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended June 30, 2026 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01.Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 13, 2026
By:
/s/ Dennis McGrath
Dennis McGrath
Chief Financial Officer
May 14, 2026 · 100% conf.
1D
-1.45%
$1.01
Act: -1.96%
5D
-8.81%
$0.93
Act: -1.96%
20D
-17.21%
$0.84
Act: -5.81%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1784724327.78503c8
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Mar 26, 2026
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1784724330.7851e5a
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Nov 12, 2025 · 100% conf.
1D
-0.89%
$1.10
Act: -3.60%
5D
-10.24%
$1.00
Act: -8.11%
20D
-22.45%
$0.86
Act: +2.70%
false 0001799011
0001799011
2025-11-12 2025-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): November 12, 2025
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
360 Madison Avenue, 25th Floor, New York, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (917) 813-1828
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November12, 2025, Lucid Diagnostics Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended September 30, 2025 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01.Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 12, 2025
By:
/s/ Dennis McGrath
Dennis McGrath
Chief Financial Officer
3
Aug 13, 2025
false 0001799011
0001799011
2025-08-13 2025-08-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): August 13, 2025
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
360 Madison Avenue, 25th Floor, New York, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (917) 813-1828
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 13, 2025, Lucid Diagnostics Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended June 30, 2025 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 13, 2025
By:
/s/ Dennis McGrath
Dennis McGrath
Chief Financial Officer
3
May 14, 2025
false 0001799011
0001799011
2025-05-14 2025-05-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): May 14, 2025
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
360 Madison Avenue, 25th Floor, New York, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (917) 813-1828
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 14, 2025, Lucid Diagnostics Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended March 31, 2025 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 14, 2025
By:
/s/ Dennis McGrath
Dennis McGrath
Chief Financial Officer
3
Mar 25, 2025
false 0001799011
0001799011
2025-03-24 2025-03-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): March 24, 2025
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
360 Madison Avenue, 25th Floor, New York, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (917) 813-1828
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 24, 2025, Lucid Diagnostics Inc. (the “Company”) issued a press release announcing financial results for its fiscal year ended December 31, 2024 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 25, 2025
By: /s/ Dennis McGrath
Dennis McGrath
Chief Financial Officer
3
Nov 13, 2024
false 0001799011
0001799011
2024-11-13 2024-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): November 13, 2024
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
360 Madison Avenue, 25th Floor, New York, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (917) 813-1828
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 13, 2024, the Company issued a press release announcing financial results for its fiscal quarter ended September 30, 2024 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 13, 2024
By:
/s/ Dennis McGrath
Dennis McGrath
Chief Financial Officer
3
Aug 12, 2024
false 0001799011
0001799011
2024-08-12 2024-08-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): August 12, 2024
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
360 Madison Avenue, 25th Floor, New York, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (917) 813-1828
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 12, 2024, the Company issued a press release announcing financial results for its fiscal quarter ended June 30, 2024 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 12, 2024
By:
/s/ Dennis McGrath
Dennis McGrath
Chief Financial Officer
3
May 14, 2024
false 0001799011
0001799011
2024-05-13 2024-05-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): May 13, 2024
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
360 Madison Avenue, 25th Floor, New York, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (917) 813-1828
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 13, 2024, the Company issued a press release announcing financial results for its fiscal quarter ended March 31, 2024 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
1
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 14, 2024
By:
/s/ Dennis McGrath
Dennis McGrath
Chief Financial Officer
2
Nov 14, 2023
false 0001799011
0001799011
2023-11-13 2023-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): November 13, 2023
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
360 Madison Avenue, 25th Floor, New York, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (917) 813-1828
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 13, 2023, the Company issued a press release announcing financial results for its fiscal quarter ended September 30, 2023 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 13, 2023
By:
/s/ Dennis McGrath
Dennis McGrath
Chief Financial Officer
Mar 14, 2023
0001799011 false
0001799011
2023-03-13 2023-03-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): March 13, 2023
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
360 Madison Avenue, 25th Floor, New York, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (212) 949-4319
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a Material Definitive Agreement.
On March 13, 2023, Lucid Diagnostics Inc. (the “Lucid Diagnostics” or the “Company”) entered into a securities purchase agreement (the “SPA”) with an accredited investor (the “Investor”), for the sale of a Senior Secured Convertible Notes in initial principal amount of up to $11,111,110 (the “Note”), in a private placement (the “Offering”). The Company expects to consummate the closing for the sale of the Note, which is subject to customary closing conditions, on or about March 21, 2023. The Company will not pay any selling commission to any party in connection with the Offering. The Note will be sold at an original issue discount of 10%.
The Company estimates that the net cash proceeds will be approximately $9.8 million from the issuance of the Note, after deducting the original issue discount and the estimated expenses of the Offering.
The Investor holds senior secured convertible notes issued by PAVmed Inc. (“PAVmed”), the Company’s parent, with an outstanding principal balance of $32.7 million. For more information, see the Current Report on Form 8-K filed by PAVmed on April 4, 2022.
SPA
The SPA contains certain representations and warranties, covenants and indemnities customary for similar transactions. Under the SPA, the Company also agreed to the following additional covenants:
● During the period through and including the 90th day after the maturity date of the Note (or such later date as is agreed between the parties), the Company may not issue any securities that would cause a breach of the Note, file a registration statement under the Securities Act of 1933, as amended (the “Securities Act”), relating to any securities other than the shares underlying the Notes or the Company’s Series A preferred stock, or issue, offer, sell, grant any option or right to purchase, or otherwise dispose of any equity or equity-linked or related security, any debt, any preferred stock (other than up to $6,375,000 shares of the Company’s Series A preferred stock) or any purchase rights, subject to certain exceptions, including issuances at a price greater than $5.00 per share.
● So long as the Note remains outstanding, the Company will not effect or enter an agreement to effect any variable rate transaction.
● The Company will hold a stockholder meeting, by no later than July 31, 2023, to approve resolutions (the “Stockholder Resolutions”) authorizing (i) an increase in the authorized shares of the Company’s common stock from 100 million to 200 million shares, and (ii) the issuance of shares of the Company’s common stock under the Notes for the purposes of compliance with the stockholder approval rules of The Nasdaq Stock Market LLC (“Nasdaq”). The Company will be obligated to continue to seek stockholder approval quarterly until such
Nov 14, 2022
0001799011 false
0001799011
2022-11-14 2022-11-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): November 14, 2022
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
One Grand Central Place, Suite 4600, New York, New York
10165
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (212) 949-4319
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 14, 2022, Lucid Diagnostics Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended September 30, 2022 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 14, 2022
By: /s/ Dennis McGrath
Dennis McGrath
Chief Financial Officer
Aug 15, 2022
0001799011 false
0001799011
2022-08-15 2022-08-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): August 15, 2022
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
One Grand Central Place, Suite 4600, New York, New York
10165
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (212) 949-4319
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 15, 2022, Lucid Diagnostics Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended June 30, 2022 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01.Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 15, 2022
By:
/s/ Dennis McGrath
Dennis McGrath
Chief Financial Officer
May 12, 2022
0001799011 false
0001799011
2022-05-11 2022-05-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): May 11, 2022
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
One Grand Central Place, Suite 4600, New York, New York
10165
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (212) 949-4319
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 11, 2022, Lucid Diagnostics Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended March 31, 2022 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 12, 2022
By: /s/ Dennis M. McGrath
Dennis M. McGrath
Chief Financial Officer
Mar 29, 2022
0001799011 true
0001799011
2022-03-28 2022-03-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
(Amendment No. 1)
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): March 28, 2022
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
One Grand Central Place, Suite 4600, New York, New York
10165
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (212) 949-4319
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
On March 28, 2022, Lucid Diagnostics Inc. (the “Company”) furnished a Current Report on Form 8-K (“Original Form 8-K”) with the U.S. Securities and Exchange Commission to report that, on March 28, 2022, the Company issued a press release announcing financial results for its fiscal year ended December 31, 2021 and providing a business update (the “Original Earnings Release”). This Amendment No. 1 to the Original Form 8-K is being furnished to disclose a joint press release (the “Earnings Update Release”) of the Company and its majority owner, PAVmed Inc. (“PAVmed”), which includes an adjustment to Footnote #3 in the Original Earnings Release relating to the Company’s Non-GAAP measures for the allocation of Total Operating expenses for the fourth quarter.
Item 2.02. Results of Operations and Financial Condition.
On March 28, 2022, the Company issued the Original Earnings Release. On March 29, 2022, the Company and PAVmed issued the Earnings Update Release, which includes an adjustment to one line item in the Original Earnings Release as described above. A copy of the Earnings Update Release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104.1
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 29, 2022
By: /s/ Dennis M. McGrath
Dennis M. McGrath
Chief Financial Officer
Mar 28, 2022
0001799011 false
0001799011
2022-03-28 2022-03-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): March 28, 2022
(Exact Name of Registrant as Specified in Charter)
Delaware
001-40901
82-5488042
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
Employer
Identification No.)
One Grand Central Place, Suite 4600, New York, New York
10165
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (212) 949-4319
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 28, 2022, PAVmed Inc. (the “Company”) issued a press release announcing financial results for its fiscal year ended December 31, 2021 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The disclosure set forth under Item 2.02 is incorporated herein by reference.
The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 28, 2022
By: /s/ Dennis M. McGrath
Dennis M. McGrath
Chief Financial Officer
See how LUCD stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "LUCD Lucid Diagnostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.